Roctavian: Biomarin’s First Gene Therapy For Hemophilia A Makes Headway
People with hemophilia A have a mutation in the gene responsible for producing factor VIII, a protein that stops bleeding by helping the blood form clots. BioMarin’s new gene therapy for hemophilia A, Roctavian, delivers a functional factor VIII gene to the body to help it produce the clotting factor by itself.
More Info : https://myacare.com/blog/rocta....vian-biomarins-first

ROCTAVIAN: BIOMARIN’S FIRST GENE THERAPY FOR HEMOPHILIA A MAKES HEADWAY | Mya Care
myacare.com

ROCTAVIAN: BIOMARIN’S FIRST GENE THERAPY FOR HEMOPHILIA A MAKES HEADWAY | Mya Care

ROCTAVIAN: BIOMARIN’S FIRST GENE THERAPY FOR HEMOPHILIA A MAKES HEADWAY